Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Evaluation of Neurosecretome from Mesenchymal Stem Cells Encapsulated in Silk Fibroin Hydrogels.

Martín-Martín Y, Fernández-García L, Sanchez-Rebato MH, Marí-Buyé N, Rojo FJ, Pérez-Rigueiro J, Ramos M, Guinea GV, Panetsos F, González-Nieto D.

Sci Rep. 2019 Jun 19;9(1):8801. doi: 10.1038/s41598-019-45238-4.

2.

Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction.

Del Puerto-Nevado L, Santiago-Hernandez A, Solanes-Casado S, Gonzalez N, Ricote M, Corton M, Prieto I, Mas S, Sanz AB, Aguilera O, Gomez-Guerrero C, Ayuso C, Ortiz A, Rojo F, Egido J, Garcia-Foncillas J, Minguez P, Alvarez-Llamas G; DiabetesCancerConnect Consortium.

Mol Oncol. 2019 Jun 14. doi: 10.1002/1878-0261.12531. [Epub ahead of print]

3.

High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Perez-Buira S, Rojo F, Costa-Garcia M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martinez-Garcia M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, Lopez-Botet M.

Cancer Immunol Res. 2019 Jun 12. pii: canimm.0896.2018. doi: 10.1158/2326-6066.CIR-18-0896. [Epub ahead of print]

PMID:
31189644
4.

Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models.

Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpí O, Menéndez S, Soria-Jimenez L, Martínez A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J.

Mol Cancer Res. 2019 Jun 3. pii: molcanres.0923.2018. doi: 10.1158/1541-7786.MCR-18-0923. [Epub ahead of print]

PMID:
31160383
5.

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z.

6.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M.

Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.

7.

Post-translational regulation could determine functional differences between SET alpha and beta isoforms in chronic lymphocytic leukaemia.

Cristóbal I, Sanz-Alvarez M, Luque M, Rojo F, García-Foncillas J.

Br J Haematol. 2019 Apr 24. doi: 10.1111/bjh.15935. [Epub ahead of print] No abstract available.

PMID:
31020656
8.

Combining electrokinetic transport and bioremediation for enhanced removal of crude oil from contaminated marine sediments: Results of a long-term, mesocosm-scale experiment.

Cappello S, Cruz Viggi C, Yakimov M, Rossetti S, Matturro B, Molina L, Segura A, Marqués S, Yuste L, Sevilla E, Rojo F, Sherry A, Mejeha OK, Head IM, Malmquist L, Christensen JH, Kalogerakis N, Aulenta F.

Water Res. 2019 Jun 15;157:381-395. doi: 10.1016/j.watres.2019.03.094. Epub 2019 Apr 3.

PMID:
30974287
9.

Letter by Cristóbal et al Regarding Article, "Protein Phosphatase 2A Regulates Cardiac Na+ Channels".

Cristóbal I, Sanz-Alvarez M, Luque M, Rojo F, García-Foncillas J.

Circ Res. 2019 Apr 12;124(8):e59. doi: 10.1161/CIRCRESAHA.119.314905. No abstract available.

PMID:
30973817
10.

Pseudomonas putida KT2440 metabolism undergoes sequential modifications during exponential growth in a complete medium as compounds are gradually consumed.

Molina L, Rosa R, Nogales J, Rojo F.

Environ Microbiol. 2019 Apr 5. doi: 10.1111/1462-2920.14622. [Epub ahead of print]

PMID:
30951237
11.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P.

Sci Rep. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y.

12.

The Role of MicroRNAs in Hepatoblastoma Tumors.

Cristóbal I, Sanz-Álvarez M, Luque M, Caramés C, Rojo F, García-Foncillas J.

Cancers (Basel). 2019 Mar 22;11(3). pii: E409. doi: 10.3390/cancers11030409. Review.

13.

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer.

Cristóbal I, Torrejón B, Rubio J, Santos A, Pedregal M, Caramés C, Zazo S, Luque M, Sanz-Alvarez M, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

J Clin Med. 2019 Mar 12;8(3). pii: E346. doi: 10.3390/jcm8030346.

14.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Erratum in: Sci Rep. 2019 May 17;9(1):7706.

15.

Molecular evidence of field cancerization initiated by diabetes in colon cancer patients.

Del Puerto-Nevado L, Minguez P, Corton M, Solanes-Casado S, Prieto I, Mas S, Sanz AB, Gonzalez-Alonso P, Villaverde C, Portal-Nuñez S, Aguilera O, Gomez-Guerrero C, Esbrit P, Vivanco F, Gonzalez N, Ayuso C, Ortiz A, Rojo F, Egido J, Alvarez-Llamas G, Garcia-Foncillas J; DiabetesCancerConnect Consortium.

Mol Oncol. 2019 Apr;13(4):857-872. doi: 10.1002/1878-0261.12438. Epub 2019 Feb 16.

16.

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Antolín S, Atienza M, Montaño Á, Ribelles N, Urruticoechea A, Falcón A, Pernas S, Orlando J, Montero JC, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A, Ruiz-Borrego M.

Breast Cancer Res Treat. 2019 Apr;174(3):693-701. doi: 10.1007/s10549-018-05100-z. Epub 2019 Jan 3.

PMID:
30607629
17.

Religiosity and health: A global comparative study.

Zimmer Z, Rojo F, Ofstedal MB, Chiu CT, Saito Y, Jagger C.

SSM Popul Health. 2018 Nov 15;7:006-6. doi: 10.1016/j.ssmph.2018.11.006. eCollection 2019 Apr.

18.

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J.

Clin Cancer Res. 2019 Mar 1;25(5):1535-1545. doi: 10.1158/1078-0432.CCR-18-2365. Epub 2018 Dec 6.

PMID:
30523021
19.

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma.

Nájera L, Alonso-Juarranz M, Garrido M, Ballestín C, Moya L, Martínez-Díaz M, Carrillo R, Juarranz A, Rojo F, Cuezva JM, Rodríguez-Peralto JL.

Br J Dermatol. 2018 Dec 7. doi: 10.1111/bjd.17513. [Epub ahead of print]

PMID:
30537064
20.

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.

García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R, Muinelo-Romay L, Montagut C, Antón A, López G, Díaz-Rubio E, Rojo F, Vivancos A.

Br J Cancer. 2018 Dec;119(12):1464-1470. doi: 10.1038/s41416-018-0293-5. Epub 2018 Nov 23.

21.

Novel regulatory mechanism of establishment genes of conjugative plasmids.

Val-Calvo J, Luque-Ortega JR, Crespo I, Miguel-Arribas A, Abia D, Sánchez-Hevia DL, Serrano E, Gago-Córdoba C, Ares S, Alfonso C, Rojo F, Wu LJ, Boer DR, Meijer WJJ.

Nucleic Acids Res. 2018 Dec 14;46(22):11910-11926. doi: 10.1093/nar/gky996.

22.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A.

Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6.

23.

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.

Prieto-Potin I, Montagut C, Bellosillo B, Evans M, Smith M, Melchior L, Reiltin W, Bennett M, Pennati V, Castiglione F, Bürrig KF, Cooper U, Dockhorn-Dworniczak B, Rossenbach C, Luna-Aguirre CM, Barrera-Saldaña HA, Machado JC, Costa JL, Yacobi R, Tabibian-Keissar H, Buglioni S, Ronchetti L, Douglas-Berger L, Dubbink HJ, Alorini M, Sabourin JC, Rojo F.

J Mol Diagn. 2018 Sep;20(5):664-676. doi: 10.1016/j.jmoldx.2018.05.008. Epub 2018 Jun 26.

PMID:
29959022
24.

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.

Ruiz-Borrego M, Jimenez B, Antolín S, García-Saenz JA, Corral J, Jerez Y, Trigo J, Urruticoechea A, Colom H, Gonzalo N, Muñoz C, Benito S, Caballero R, Bezares S, Carrasco E, Rojo F, Martín M.

Invest New Drugs. 2019 Feb;37(1):98-108. doi: 10.1007/s10637-018-0614-9. Epub 2018 Jun 9.

PMID:
29948356
25.

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Aug;20(8):1093-1095. doi: 10.1007/s12094-018-1909-1.

PMID:
29916189
26.

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.

Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, García-Albéniz X, Maurel J.

Neoplasia. 2018 Jul;20(7):678-686. doi: 10.1016/j.neo.2018.05.004. Epub 2018 May 26.

27.

Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.

Torrejón B, Cristóbal I, Caramés C, Prieto-Potín I, Chamizo C, Santos A, Sanz-Alvarez M, Serna-Blasco R, Luque M, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

World J Surg. 2018 Nov;42(11):3771-3778. doi: 10.1007/s00268-018-4684-9.

PMID:
29796729
28.

Dissecting the therapeutic implications of the complex SMAD4 regulatory network in metastatic colorectal cancer.

Cristóbal I, Torrejón B, Santos A, Luque M, Sanz-Alvarez M, Rojo F, García-Foncillas J.

Eur J Surg Oncol. 2018 Aug;44(8):1283-1284. doi: 10.1016/j.ejso.2018.04.021. Epub 2018 May 9. No abstract available.

PMID:
29778618
29.

Potential Therapeutic Impact of miR-145 Deregulation in Colorectal Cancer.

Cristóbal I, Sanz-Alvarez M, Torrejón B, Santos A, Luque M, Rojo F, García-Foncillas J.

Mol Ther. 2018 Jun 6;26(6):1399-1400. doi: 10.1016/j.ymthe.2018.05.008. Epub 2018 May 18. No abstract available.

30.

Influence of the Hfq and Crc global regulators on the control of iron homeostasis in Pseudomonas putida.

Sánchez-Hevia DL, Yuste L, Moreno R, Rojo F.

Environ Microbiol. 2018 Oct;20(10):3484-3503. doi: 10.1111/1462-2920.14263. Epub 2018 Aug 5.

PMID:
29708644
31.

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Aug;20(8):990. doi: 10.1038/s41556-018-0052-0.

PMID:
29674681
32.

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

Chin SF, Santonja A, Grzelak M, Ahn S, Sammut SJ, Clifford H, Rueda OM, Pugh M, Goldgraben MA, Bardwell HA, Cho EY, Provenzano E, Rojo F, Alba E, Caldas C.

Exp Mol Pathol. 2018 Jun;104(3):161-169. doi: 10.1016/j.yexmp.2018.03.006. Epub 2018 Mar 31.

33.

[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R.

Rev Esp Patol. 2018 Apr - Jun;51(2):97-109. doi: 10.1016/j.patol.2017.12.002. Epub 2018 Mar 14. Spanish.

PMID:
29602380
34.

Comment on 'MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma'.

Cristóbal I, Santos A, González S, Luque M, Torrejón B, Rojo F, García-Foncillas J.

Br J Cancer. 2018 Apr;118(7):1028-1029. doi: 10.1038/s41416-018-0013-1. Epub 2018 Mar 19. No abstract available.

35.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

PMID:
29530933
36.

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Feb;20(2):211-221. doi: 10.1038/s41556-017-0021-z. Epub 2018 Jan 22. Erratum in: Nat Cell Biol. 2018 Apr 19;:.

PMID:
29358704
37.

Potential contribution of SET and c-MYC deregulation to promote extracellular matrix remodelling in hepatocellular carcinoma.

Cristóbal I, Torrejón B, Rojo F, García-Foncillas J.

Br J Pharmacol. 2018 Feb;175(3):573-574. doi: 10.1111/bph.14108. Epub 2018 Jan 5. No abstract available.

38.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Jul;20(7):815-826. doi: 10.1007/s12094-017-1800-5. Epub 2017 Dec 22. Review. Erratum in: Clin Transl Oncol. 2018 Jun 18;:.

39.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Review.

40.

DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells.

Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, Dopazo A, Rojo F, Belda C, Alvarez R, Valentin J, Benitez J, Perona R, De Castro J, Ibanez de Caceres I.

Theranostics. 2017 Sep 22;7(17):4118-4134. doi: 10.7150/thno.20112. eCollection 2017.

41.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J.

Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9.

42.

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

Manso R, Sánchez-Beato M, González-Rincón J, Gómez S, Rojo F, Mollejo M, García-Cosio M, Menárguez J, Piris MA, Rodríguez-Pinilla SM.

Br J Haematol. 2018 Nov;183(3):497-501. doi: 10.1111/bjh.14984. Epub 2017 Oct 26. No abstract available.

PMID:
29076126
43.

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A.

Oncotarget. 2017 Apr 14;8(42):73144-73153. doi: 10.18632/oncotarget.17113. eCollection 2017 Sep 22.

44.

Differential expression of the three Alcanivorax borkumensis SK2 genes coding for the P450 cytochromes involved in the assimilation of hydrocarbons.

Sevilla E, Yuste L, Moreno R, Rojo F.

Environ Microbiol Rep. 2017 Dec;9(6):797-808. doi: 10.1111/1758-2229.12598. Epub 2017 Nov 9.

PMID:
29052944
45.

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.

Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, Gomis RR.

Lancet Oncol. 2017 Nov;18(11):1543-1552. doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13.

PMID:
29037984
46.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Review.

47.

PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications.

Cristóbal I, Torrejón B, Martínez-Useros J, Madoz-Gurpide J, Rojo F, García-Foncillas J.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):435-438. doi: 10.1016/j.bbcan.2017.08.005. Epub 2017 Sep 12. Review.

PMID:
28916342
48.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

49.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

50.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

Supplemental Content

Support Center